Table 2. Significantly dysregulated lncRNAs in hepatitis comparisons.
| HBV+ HCV- HCC versus normal liver | HBV- HCV+ HCC versus normal liver | HBV+ HCV+ HCC versus normal liver | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fold change | logCPM | P value | FDR | Fold change | logCPM | P value | FDR | Fold change | logCPM | P value | FDR | |
| lnc-AFM-2:1 | 20.14 | 6.75 | 4.49E-13 | 2.01E-12 | 5.09 | 4.39 | 3.56E-06 | 1.25E-05 | 17.73 | 6.24 | 4.79E-13 | 4.95E-12 |
| lnc-C9orf16-3:1 | 22.05 | 5.23 | 3.93E-21 | 4.43E-20 | 26.71 | 4.87 | 3.37E-23 | 2.28E-21 | 26.02 | 5.18 | 1.20E-21 | 4.30E-20 |
| lnc-CASD1-3:1 | 40.16 | 7.23 | 4.67E-19 | 4.08E-18 | 23.03 | 5.79 | 3.96E-16 | 8.37E-15 | 36.30 | 6.77 | 1.11E-22 | 4.51E-21 |
| lnc-FBXO42-1:1 | –4.70 | 3.05 | 5.63E-11 | 2.00E-10 | –4.34 | 3.76 | 1.92E-08 | 1.07E-07 | –13.40 | 3.57 | 1.56E-26 | 1.05E-24 |
| lnc-INS-IGF2-1:3 | –6.76 | 3.50 | 1.11E-11 | 4.25E-11 | –6.59 | 4.20 | 1.00E-07 | 4.89E-07 | –12.16 | 4.06 | 1.57E-14 | 2.04E-13 |
| lnc-MT1X-1:4 | –5.29 | 8.47 | 2.64E-12 | 1.08E-11 | –3.63 | 9.26 | 2.22E-06 | 8.15E-06 | –13.09 | 9.05 | 5.67E-23 | 2.37E-21 |
| lnc-NT5DC3-1:2 | –12.05 | 2.76 | 4.02E-87 | 1.22E-82 | –12.30 | 3.55 | 5.68E-32 | 1.39E-29 | –11.81 | 3.49 | 1.75E-38 | 6.62E-36 |
| lnc-PKD2-2:1 | 22.55 | 5.48 | 1.02E-16 | 6.84E-16 | 13.79 | 4.17 | 1.59E-17 | 4.17E-16 | 20.68 | 5.05 | 1.52E-20 | 4.68E-19 |
| lnc-POTEM-2:21 | 13.95 | 3.80 | 1.12E-34 | 6.20E-33 | 13.03 | 3.13 | 7.15E-36 | 2.83E-33 | 16.44 | 3.78 | 6.59E-49 | 1.51E-45 |
| lnc-SLC25A48-3:1 | –6.90 | 3.75 | 8.34E-14 | 4.05E-13 | –9.83 | 4.43 | 1.14E-15 | 2.20E-14 | –16.38 | 4.32 | 1.14E-22 | 4.63E-21 |